TickerTalks
Browse all tickers →
TickerTalks›$PAVS
PAPAVS

Paranovus Entertainment Technology Ltd.

$PAVS·$4M·Medical - Pharmaceuticals·Healthcare
$6.99+5.6%YTD-99.8%1Y-100.0%
Mentions · last 7 days
2026-08-08: 15 posts2026-08-09: 36 posts2026-08-10: 60 posts2026-08-11: 31 posts2026-08-12: 15 posts2026-08-13: 9 posts2026-08-14: 8 posts1740%
Price updated 2d ago·X counts updated 2d ago
PAPAVS
$PAVSParanovus Entertainment Technology Ltd.
$6.99+5.59%174 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $PAVS, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Broken storySelling offAI verdict · as of 2026-08-15

Falling on heavy selling — points lower unless it turns around.

Paranovus down 99.8% YTD after a 1-for-100 reverse split and a $10M dilutive offering — this is a broken-story microcap trading on low-float pump mechanics.

Paranovus Entertainment Technology is a Chinese AI-entertainment microcap — AI-driven games and applications. The equity is essentially unrecognizable versus a year ago: down 99.8% YTD after a 1-for-100 reverse split and a $10M dilutive registered-direct offering, and now trades on pure low-float pump mechanics.

Where it stands:

  • The dilution and reverse-split are the definitional value-destruction combination: a 1-for-100 reverse share split completed June 25, plus a $10M registered direct offering (9.3M Class A shares at $0.20/share plus 40.7M pre-funded warrants) — the equity base is being remade in a way that has destroyed 99.8%+ of shareholder value YTD.
  • The financial reality is extreme: Q3 FY25 revenue of $12.4M was a huge sequential jump from $3K in Q1, but that's off a broken base, and EPS of -$0.97 continues the operating-loss pattern. Consensus estimates from a single analyst modeling FY27 revenue at $72M and $80M in FY28 are aggressive projections against the current trajectory.
  • The Jabanero acquisition LOI plus the current $4M market cap on 856K shares of float is the specific pump-and-dump setup: 40-150% intraday spikes with 30-49% premarket-alert gains grouping PAVS alongside other China low-floater pumps (CLRO, WYHG, LBGJ, YXT) — this trades on float mechanics, not fundamentals.

The story stops falling if the Jabanero LOI converts into a substantive acquisition with real revenue attached and the ATM/dilution activity pauses. What seals the breakdown: continued sub-$1M float trading with 40-150% intraday reversals and no fundamental catalyst — this is a pattern that historically ends in Nasdaq delisting or reverse-merger repurposing.

Differs from X sentimentDisagree with the promotional low-float pump framing — the ascending-triangle $12-16 target chatter is textbook low-float China-runner mechanics grouped with CLRO/WYHG/LBGJ/YXT peers, not a fundamental setup. The actual equity is down 99.8% YTD after a 1-for-100 reverse split and dilutive $10M offering; celebrating 30-49% premarket alerts on a broken-story microcap without commercial substance is not an investable setup.

What to watch: The Jabanero acquisition LOI conversion into a substantive deal with real revenue attached — plus a pause in ATM/dilution activity — is what stops the fall. Continued sub-$1M float trading with 40-150% intraday reversals and no fundamental catalyst is the pattern that historically ends in Nasdaq delisting or reverse-merger repurposing.

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment35 posts analyzed · as of 2026-08-13

Paranovus spikes 40-150% intraday as a low-float Chinese microcap runner, with users citing sub-1M float, 6-K filing overnight, ascending-triangle break above $10 and target ranges of $12-16. Small-cap traders celebrate 30-49% gains from premarket alerts, grouping it with CLRO, WYHG, LBGJ and YXT as pump-and-dump China low-floater plays.

Read the AI verdict + X sentiment for $PAVS

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

AI-powered gaming and entertainment app company, formerly Happiness Development Group, focused on AI-driven consumer applications.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Pharmaceuticals sits in its cycle right now — and what that implies for $PAVS.

Medical - Pharmaceuticals · Healthcare

No material change from last week — Trump's executive order support and DEA rescheduling progress create a viable regulatory pathway while ATAI's pipeline advances toward multiple late-stage data..

What this means for $PAVS

Neutral — AI-powered gaming and entertainment app company, formerly Happiness Development Group, focused on AI-driven consumer applications; limited read-through from medical - pharmaceuticals macro dynamics to this specific revenue mix.

Industry benchmark

5-name peer basket
+90.7%YTD
+65.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-0.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-5.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-14.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-0.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
30.1Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-26.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
9.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q3 2025Nov 3, 2025$-0.97——
Q2 2025Aug 15, 2025$-47.52$4080.00-101.2%
Q3 2024Oct 30, 2024$-8.68——
Q2 2024Aug 1, 2024$-39.19——
Next earningsFri, Jan 15

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY25$12.4M—11.3%-5.1%$-0.97$-159K
Q4 FY24$3K-100.0%-6161%-36992%$-10.17$-1.7M
Q2 FY24$68K-99.6%-264%-1690%$-8.68$-966K
Q4 FY23$0-100.0%——$-39.19$900

Forward consensus

3-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY27$72.2M$72.2M – $72.2M$2112000.00$2112000.00 – $2112000.001
FY28$80.1M$80.1M – $80.1M$840000.00$840000.00 – $840000.001
FY29$88.9M$88.9M – $88.9M$1152000.00$1152000.00 – $1152000.001

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.0%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-56.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-99.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Jun 16424B5
AI summary

Paravision filed a 424B5 for an offering of 9,300,000 Class A ordinary shares at $0.20/share plus 40,700,000 pre-funded warrants ($0.0001 exercise price), for a combined approximately $10M gross. Deeply dilutive micro-cap offering at $0.20/share.

424B5Prospectus supplement (offering)Jun 9424B5
AI summary

Paravision filed a 424B5 for an ATM prospectus allowing sales of Class A ordinary shares up to approximately $195M aggregate through AC Sunshine as sales agent; at a prior price of $0.20/share, this represents potential for very large dilution if fully utilized. Massive ATM facility relative to share price; extreme dilution potential.

3New insider — initial holdingsApr 63
424B5Prospectus supplement (offering)Mar 25424B5
3New insider — initial holdingsMar 203
3New insider — initial holdingsMar 203
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
+ 16 other (13 6-Ks · 1 20-F · 1 NT 20-F · 1 3) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Paranovus Entertainment Technology Limited Announces 1-For-100 Reverse Share Splitaccessnewswire.com·52d agoPAVS Announces Pricing of a $10 Million Registered Direct Offering of Class A Ordinary Shares and Pre-Funded Warrantsglobenewswire.com·62d agoPAVS Announces Pricing of a $10 Million Registered Direct Offering of Class A Ordinary Shares and Pre-Funded Warrantsprnewswire.com·62d agoPAVS Announces Termination of the Sales Agreement for its At-the-Market Offering with AC Sunshine Securitiesaccessnewswire.com·62d agoParanovus Entertainment Technology Limited Signs Non-Binding Letter of Intent to Acquire Jabanero Inc.accessnewswire.com·62d ago

More in Medical - Pharmaceuticals

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LQDA$CORT$KNSA$CIRC$SGIPF$UCBJF
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport